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Glaucoma is a multi-factorial blinding disease in which genetic factors play an important role.
Elevated intraocular pressure is a highly heritable risk factor for primary open angle glaucoma
and currently the only target for glaucoma therapy. Our study helps to better understand
underlying genetic and molecular mechanisms that regulate intraocular pressure, and iden-
tiﬁes a new candidate gene, Cacna2d1, that modulates intraocular pressure and a promising
therapeutic, pregabalin, which binds to CACNA2D1 protein and lowers intraocular pressure
signiﬁcantly. Because our study utilizes a genetically diverse population of mice with known
sequence variants, we are able to determine that the intraocular pressure-lowering effect of
pregabalin is dependent on the Cacna2d1 haplotype. Using human genome-wide association
study (GWAS) data, evidence for association of a CACNA2D1 single-nucleotide polymorph-
ism and primary open angle glaucoma is found. Importantly, these results demonstrate that
our systems genetics approach represents an efﬁcient method to identify genetic variation
that can guide the selection of therapeutic targets.
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Primary open angle glaucoma (POAG) is a leading cause ofblindness worldwide1. The disease is characterized byprogressive optic nerve damage arising from apoptotic cell
death of retinal ganglion cells. Elevated intraocular pressure (IOP)
is one of the most signiﬁcant risk factors contributing to visual
ﬁeld loss in this disease. Steady-state IOP is generated by the
balance of aqueous humor (AH) production by the ciliary body
(CB) and AH drainage through the trabecular meshwork (TM;
conventional pathway), and to a lesser degree the uveoscleral or
nonconventional pathway. An imbalance between the inﬂow and
outﬂow of AH leads to a change in IOP2–4. Gene variants
inﬂuence an individual’s likelihood of developing glaucoma, the
rate of disease progression, and how a patient responds to
treatment. Because IOP can be medically controlled, IOP reduc-
tion is the ﬁrst-line therapeutic option in glaucoma. Current
medications do not address the underlying pathologies that lead
to elevated IOP, nor do they address the many potential sources
of variation related to IOP modulation.
Both POAG and IOP are highly heritable. In humans, IOP
heritability is estimated to be ~55%. Moreover, the genetic risk of
elevated IOP and POAG are partially shared5, 6, although some
loci that are associated with POAG were not associated with
IOP7. To date, multiple candidate IOP or POAG loci have been
identiﬁed (e.g., TMCO1, CDKN2B-AS1, GAS7, CAV1/CAV2,
SIX1/SIX6, TXNRD2, ATXN2, FOXC1 ABCA1, AFAP1, GMDS,
PMM2, TGFBR3 ARHGEF12, FAM125B, FNDC3B, and the ABO
blood group), however, their physiological roles are not well
understood7–16. Identiﬁcation of additional gene variants that
modulate IOP both in animals and humans is therefore likely to
provide critical insights and new targets for therapeutic
intervention.
Systems genetics is an extension of complex trait analysis that
examines large sets of genotypes and phenotypes to investigate
the genetic basis of disease traits17–20. The BXD family is cur-
rently the largest and best characterized mouse genetic reference
population21. This family is an admixture of C57BL/6J and DBA/
2J genomes, and the family are segregating for roughly 5.5 million
sequence variants22. Over the last decade, the BXD family has
become a key resource for systems genetics largely because they
have been phenotyped so thoroughly and at many levels—from
messenger RNA (mRNA) to maternal behavior17, 23–25. There is
also extensive phenome data on the visual system of these
strains26–30. One of the major advantages of the BXDs relative to
the Collaborative Cross and other new resources is that the DBA/
2J progenitor strain and many of the BXD progeny strains con-
sistently develop high IOP between 6 and 10 months of age31.
Therefore, they are an ideal resource to discover gene variants
that modulate both IOP and glaucoma.
In this study, we systematically measure IOP across a large
subset of the BXD family in multiple age cohorts. Using stringent
stepwise reﬁnement based on expression quantitative trait locus
(QTL) mapping, correlation analyses (direct and partial Pearson
test), and the analysis of single-nucleotide polymorphisms
(SNPs), we identify a candidate gene that modulates IOP, and we
combine mouse and human genetic data in an effort to validate
the candidate gene. Lastly, we evaluate the IOP-lowering effect of
a drug speciﬁcally targeted to the candidate protein product.
Collectively, our study ﬁnds that Cacna2d1 modulates IOP and
that blocking the function of its gene product, CACNA2D1, with
pregabalin reduces IOP in a dose-dependent and haplotype-
speciﬁc manner.
Results
Study design. A major advantage of the genetically diverse BXD
family over non-inbred strains is that each strain is homozygous
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Fig. 1 Overview of IOP systems genetics analyses. a BXD strains derived by
crossing C57BL/6J (B6) and DBA/2J (D2) parents. The resulting
heterozygous F1 mice were crossed to generate genetically diverse but non-
reproducible F2 animals. These F2 progeny were iteratively inbred until
generation F20+, at which point each strain represents a unique mosaic of B
and D alleles. b Workﬂow for IOP systems genetics analysis. IOP was
measured from 65 BXD strains aged 9.1–13 months. Genomic regions
modulating IOP were identiﬁed using QTL analyses. Stringent reﬁnement
based on QTL mapping, correlation analyses, and SNPs was performed to
identify positional candidate genes. Subcellular localization of candidates in
mouse and human eyes were determined by immunohistochemistry. The
NEIGHBORHOOD consortium database was used to identify SNPs within
the candidate gene associated with elevated IOP and POAG in humans. The
IOP-lowering effect of pregabalin, a drug with high afﬁnity for CACNA2D1
was evaluated as eye drops in D2, BXD48 (D allele), B6, and BXD14 (B
allele) strains for validation
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across its genome (Fig. 1a), which allows for an inﬁnite source of
genetically identical test subjects. IOP is one factor that can
inﬂuence glaucoma risk. To identify a gene candidate that
modulates IOP, we utilized a systems genetics, pharmacological,
and translational approach (Fig. 1b). We have successfully used
this approach in previous studies to identify gene modulators of
various traits in BXD mice26, 27, 29, 30, 32, 33.
Trait and genetic variation across BXD mice. IOP varied over
twofold in 9.1–13-month-old BXD strains (range of 9.6± 0.92
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mmHg in BXD38 to 19.38± 0.43 mmHg in BXD14; Fig. 2a).
IOP heritability was 31%, which is comparable to that of other
ocular traits to which QTL mapping has been applied
successfully27, 29, 32–34. There was no statistically signiﬁcant
difference in IOP between the sexes (Fig. 2b).
The variation in IOP was mapped to a narrow locus on
proximal Chr 5 (likelihood ratio statistic (LRS)= 19.6, logarithm
of the odds (LOD)= 4.25, Fig. 2c). This QTL was not associated
with IOP in studies using younger sex-matched BXD strains,
suggesting that the QTL contains gene variants that contribute to
variation in IOP at an older age29. In addition, the location of this
LRS interval does not overlap with the location of either Tyrp1 or
Gpnmb (Fig. 2c). As conﬁrmation that the well-documented
mutations in Tyrp1 and Gpnmb do not inﬂuence IOP in the BXD
GRP, IOP also maps to the same location on Chr 5 after we
exclude strains that harbor both mutations or harbor only one of
the mutations (Supplementary Fig. 1). Moreover, the complete
overlap of IOP distributions for all possible genotypes at those
two loci (P= 0.13; Fig. 2d) further supports this claim.
Selection of positional candidates in the chromosome 5 locus.
To determine the candidate gene variants that modulate IOP
within the Chr 5 locus, we used the following stringent criteria
(Fig. 2e): (1) the gene is located within the conﬁdence interval of
the peak eQTL; (2) the gene has cis-modulation; (3) the expres-
sion level of the gene across BXD strains is signiﬁcantly correlated
with elevated IOP using both linear correlation and partial
Pearson correlation analyses; (4) the gene functions within a
network that could explain its role in modulating IOP; (5) the
gene has sequence variants between parental strains at/near the
region of the gene; (6) the gene is expressed in the eye and
localized to an area associated with modulation of IOP; (7) the
gene is associated with human POAG and/or elevated IOP either
through GWAS or standard linkage studies; and (8) the gene has
a biological association with glaucoma or its treatment.
Within the QTL peak at Chr 5, there were 25 positional gene
candidates that were cis-regulated (Supplementary Table 1).
Using our above criteria, calcium channel, voltage-dependent,
α2δ1subunit (Cacna2d1) emerged as the single best positional
candidate (r= 0.440; P = 0.0003; Fig. 2f). No other positional
candidate fulﬁlled our selection criteria (Supplementary Table 2).
Gene set enrichment analyses (GSEA; Broad Institute35)
determined that nominally signiﬁcant gene correlates of Cac-
na2d1 (Supplementary Data 1) were signiﬁcantly enriched for
plasma membrane localization (Fig. 2g) and for functions related
to neuronal function and excitability, including ion channel
activity, substrate-speciﬁc channel activity, metal ion transmem-
brane transporter activity, ion transmembrane transporter
activity, and receptor activity (Fig. 2h). These results suggest that
Cacna2d1 likely functions within pathways that critically
inﬂuence ion channels and/or their receptors within the eye that
affect IOP regulation.
Gene haplotypes of Cacna2d1 contribute to variations in IOP.
The expression of the Cacna2d1 transcript in the whole eye varied
signiﬁcantly among BXD strains (range of 6.9± 0.2 in BXD71 to
9.7± 0.3 in BXD48a), which is a 5.6-fold difference in mRNA
expression (Fig. 3a). BXD strains with the D parental allele have
lower expression of Cacna2d1 in the eye than those strains with
the B parental allele (Fig. 3a, b, P= 1.2 × 10−32). Cacna2d1
mapped as a signiﬁcant cis-eQTL (LRS= 143; LOD= 31.01) on
proximal Chr 5 at 14.3 Mb, which is within 5Mb of location of
the gene itself (Fig. 3c), making it a cis-regulated gene.
Cacna2d1 encodes for a preproprotein that is cleaved into
multiple chains that form the alpha-2 and delta subunits of the
voltage-dependent calcium channel complex. CACNA2D1 is a
glycosylphosphatidylinositol (GPI)-anchored subunit typically
associated with the Cavα1 pore within L-type calcium channels
in smooth muscle (Fig. 3d). The gene is highly polymorphic
(Fig. 3e) with 1056 SNPs and 30 insertions/deletions between the
parent strains (Supplementary Data 2). These variants segregate
among the BXD strains based upon the haplotype of the gene.
Similarly, in humans, CACNA2D1 is highly polymorphic and has
several splice variants36–38.
We further sought to determine if the Cacna2d1 haplotype
inﬂuenced the baseline IOP in BXD mice. Similar to the inﬂuence
of the parental allele on Cacna2d1 expression (Fig. 3b), we found
a distinct segregation of IOP values among the BXD strains that
was dependent upon the haplotype of Cacna2d1 that was age-
dependent. The Cacna2d1 haplotype had no signiﬁcant effect on
IOP in younger BXD strains (P= 0.34, age 1–2.1 months) (Fig. 3f,
left). In contrast, in older age (aged 9.1–13 months), strains
with Cacna2d1 inherited from the B6 parent (B allele) had
signiﬁcantly higher IOP than those with the D allele (P= 0.0008,
Fig. 3f, right).
To further assess the strength of this candidate gene, we
evaluated human POAG GWAS data from the NEIGHBOR-
HOOD consortium (N= 3853 cases and 33 480 controls)16. A
total of 1520 SNPs in the human genomic region that includes
CACNA2D1 (chromosome 7:81.9–82.4 Mb) were evaluated,
identifying nominal association for POAG (P< 0.05) for 44
SNPs (Supplementary Table 3), with the lead SNP (rs2299184
[A], P= 0.001, odds ratio= 1.15) located in intron 1 near DNaseI
hypersensitivity sites annotated by the Encyclopedia of DNA
Elements (ENCODE) as active in non-pigmented ciliary epithe-
lium. Eight of the 44 human CACNA2D1 SNPs showing nominal
association in the NEIGHBORHOOD POAG GWAS were also
included in a multi-ethnic IOP association study9, however,
Fig. 2 Association analyses reveal Cacna2d1 as a candidate for IOP modulation. a IOP levels vary among the BXD strains. IOP of BXD strains carrying
wild-type alleles of Tyrp1 and Gpnmb (WT/WT; blue bars), wild-type Tyrp1 and mutant Gpnmb (WT/MUT; green bars), mutant Tyrp1 and WT Gpnmb
(MUT/WT; yellow bars), and mutant alleles of both genes (MUT/MUT; red bars) are shown. n= 65 strains, age= 9.1–13 months. Values denote IOP
levels on mmHg scale (mean± SEM). b No differences in IOP between sexes. There is a strong statistical association between the IOP of males and
females (P< 0.0001). The relationship between the sexes is positively correlated (R2= 0.37, Pearson correlation coefﬁcient= 0.62). c Genetic interval
mapping revealed a single signiﬁcant eQTL on proximal Chr 5. This is distinct from the locations of Tyrp1 and Gpnmb in the genome (black vertical lines on
Chr 4 and Chr 6, respectively). d Tyrp1 and Gpnmb haplotypes do not inﬂuence IOP in BXD mice. The scatter plot shows average IOP of BXD strains
carrying wild-type alleles of Tyrp1 and Gpnmb (WT/WT), wild-type allele of Tyrp1 and mutant allele of Gpnmb (MUT/WT), mutant allele of Tyrp1 and wild-
type allele of Gpnmb (WT/MUT), and mutant alleles of both genes (MUT/MUT) (n= 65, P= 0.13, age= 9.1–13 months). P-value was calculated using an
ANOVA. e Stringent selection criteria for selecting candidate genes. f A signiﬁcant QTL for IOP is present on chromosome 5 between 14–19Mb. Cacna2d1
is the strongest candidate gene located in the peak QTL. g Gene set enrichment analysis for positive correlates of Cacna2d1. Gene correlates of Cacna2d1
were signiﬁcantly enriched for localization to the plasma membrane. False discovery rate (FDR) cutoff was set as q≤ 0.25. h Gene set enrichment analysis
of genes positively correlated with Cacna2d1 presented as molecular function groupings. Categories that are statistically over-represented are shown with
their normalized enrichment score (NES) listed next to the bars
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signiﬁcant association for these eight SNPs was not found in the
IOP metadata, possibly due to different genetic effects in the
multiple ethnicities included in that study.
CACNA2D1 is localized to the CB and TM in mice and
humans. To further test Cacna2d1 as a candidate IOP-
modulating gene, we performed immunohistochemistry to
determine the localization pattern of CACNA2D1 in healthy
mouse and human donor eyes. In the mouse eye, CACNA2D1 is
prominently localized to the TM, CB, and ciliary muscle (CM)
(Fig. 4a–c). CACNA2D1 was observed in a punctate pattern
throughout the TM and Schlemm’s canal. In the CB, CACNA2D1
was highly expressed in the non-pigmented epithelium. Weak
labeling was present in the CM. A similar pattern of expression
was observed in the TM and CB of the human donor eye
(Fig. 4d–f).
IOP response to pregabalin depends on Cacna2d1 genotype.
Based upon our data suggesting that Cacna2d1 modulates IOP,
we evaluated the ability of pregabalin, a gabapentinoid drug with
high speciﬁcity for CACNA2D1, to affect IOP. Our data
demonstrate that pregabalin ophthalmic eye drops reduce IOP in
mice in a dose-dependent manner (Fig. 5a). The percent reduc-
tion in IOP for both treated and control eyes after application of
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expression values from 6.9± 0.03 and 9.7± 0.10 (mean±SEM). On the Y-axis, Cacna2d1 expression is on a log2 scale. Parental strains (black), F1s (black),
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of BXD strains. BXD strains with the D parental allele have lower expression of Cacna2d1 in the eye, while those with the B parental allele have higher
expression of the gene (n= 70; P< 0.0001). P-value was calculated using an ANOVA. c Genetic mapping revealed a single highly signiﬁcant cis-eQTL for
Cacna2d1 on Chr 5. The purple triangle indicates the location of Cacna2d1 within the mouse genome. d Subunit assembly of voltage-gated calcium channels.
Graphic representation of the high voltage-activated calcium channel complex consisting of the main pore forming α1 (blue) subunit plus ancillary, β (blue),
γ (blue), and α2 (red) and δ1 (red) subunits. α2 and δ1 subunits have a disulphide bond between them. The δ1 unit is GPI-anchored to the plasma membrane.
e UCSC Genome Browser illustration of gene structure, and location of SNPs and InDels in Cacna2d1 on Chr 5 of the mouse genome. Reference Sequence
mRNA is represented in blue. f Effect of Cacna2d1 haplotype on IOP is age-dependent. In this scatter plot, parental allele of Cacna2d1 does not signiﬁcantly
inﬂuence IOP in young BXDs (P= 0.34, n= 63, age= 1–2.1 months; left). In contrast, BXD strains carrying the B parental allele of Cacna2d1 have higher IOP,
while those with the D parental allele have lower IOP in older mice (P= 0.0008, n= 64, age= 9.1–13 months; right). P-value was calculated using an
ANOVA. F1s were not included in these analyses
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our ophthalmic pregabalin eye drops (0.3–1.2%) are shown in
Fig. 5a. Table 1 lists the pharmacodynamic parameters after
application of pregabalin eye drops and statistical evaluation of
the data, respectively. Drops containing 0.3% drug provided no
IOP-lowering effect compared to control. All other concentra-
tions of drug reduced IOP in a dose-dependent manner. A pla-
teau was reached at 0.9% and there was no signiﬁcant difference
in drug response between 0.9 and 1.2% drug (P> 0.05). There
was no signiﬁcant difference between the time of maximum
response (Tmax) values of 0.6–1.2% concentrations of drug (P>
0.05). In contrast, there was a signiﬁcant difference between the
time required for IOP to return to baseline (Tend) for all con-
centrations of pregabalin eye drops, (P< 0.0001). The 1.2%
pregabalin eye drops extended the duration of the IOP-lowering
effect of pregabalin above that obtained with 0.6% pregabalin.
Because there was no signiﬁcant difference in the percent
reduction of IOP between 0.9 and 1.2% pregabalin, we selected
0.9% as the minimal concentration required to produce the
maximum reduction in IOP.
The Cacna2d1 haplotype also inﬂuenced the drug response.
Figure 5b illustrates the percent reduction in IOP after
application of 0.9% pregabalin eye drops into the eyes of DBA/
2J, BXD48 (D allele), C57BL/6J, and BXD14 (B allele) mice.
Table 2 lists the pharmacodynamic parameters after application
of 0.9% pregabalin eye drops and statistical evaluation of the data,
respectively. Mice with the B allele of Cacna2d1 (i.e., B6 and
BXD14) were more responsive to pregabalin (0.9%) eye drops
than mice with the D allele (i.e., D2 and BXD48). In addition to
larger reductions in IOP, mice with the B allele of Cacna2d1 had
larger Tmax, Tend, and area under the curve (AUCtotal) than mice
with the D allele. Expanding this analysis to an additional
species, we observed a similar IOP-lowering response (22.1±
2.8%) in Dutch belted rabbits after instillation of 0.9% pregabalin
eye drops (Fig. 5c). Table 3 lists the pharmacodynamic
parameters and statistical evaluation of the data after
application of 0.9% pregabalin eye drops into the eyes of Dutch
belted rabbits.
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Fig. 4 Cellular localization of CACNA2D1 in C57BL/6 J mouse and human donor eyes. Cellular localization of CACNA2D1 in C57BL/6J mouse and human
donor eyes. a–f Sections from C57BL/6J mouse (a–c) and human donor (d–f) iridocorneal angle were labeled with anti-CACNA2D1 antibodies. CACNA2D1
(green) is localized in the ciliary body (CB), trabecular meshwork (TM), Schlemm’s canal (SC), and ciliary muscle (CM) in both B6 mice and human donor
eyes. CACNA2D1 was also present in the posterior pigmented epithelium of the iris. n= 2 mice and 1 human. Scale: 100 µm. Blue nuclei, CB ciliary body,
CM ciliary muscle, CR cornea, IR iris, SC Schlemm’s canal, TM trabecular meshwork
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Discussion
By combining a forward murine genetics approach with cell
biology, pharmacology, and analysis of human GWAS data, we
were able to identify a genetic locus that signiﬁcantly modulates
IOP in the BXD murine genetic reference panel. Furthermore, we
have demonstrated that our top candidate gene—Cacna2d1—is
critical for modulation of IOP in these strains. Although other
positional candidates in our Chr 5 QTL, such as Nos3 and Sema3e
(Supplementary Table 1), have been linked to glaucoma39–41, they
do not fulﬁll our stringent selection criteria and therefore have
been eliminated as candidate genes (Supplementary Table 2).
Other positional candidates, such as Crygn and Klhl7, have been
associated with other ocular diseases42, 43, but not glaucoma.
We have validated Cacna2d1 using multiple stringent criteria
and identiﬁed human SNPs in the CACNA2D1 genomic region
that are nominally associated with POAG. Furthermore, we have
demonstrated that both baseline IOP and steady-state expression
of Cacna2d1 are dependent upon the parental allele of the gene in
mice. As a corollary, we further show that the response to
pregabalin, a gabapentinoid drug with high afﬁnity for
CACNA2D1, is also dependent upon the Cacna2d1 haplotype.
This is a bidirectional study that has successfully identiﬁed an
IOP-modulating candidate gene in glaucoma and demonstrated a
differential response to therapy. Our results further underscore
the potential value of using the BXD genetic reference panel as a
powerful tool to study human disease. Collectively, our data
identify CACNA2D1 as a modulator of IOP and provide an
avenue for a precision medicine approach to glaucoma therapy.
Previous studies have demonstrated a link between Ca2+,
calcium channels and glaucoma44–53, providing a historical
backdrop for our discovery of the role of Cacna2d1 in
IOP modulation. Because Ca2+ likely plays a role in the patho-
physiology of glaucoma45, systemic calcium channel blockers
(CCBs) (e.g., verapamil, diltiazem, or nimodipine) have been
evaluated as plausible therapies for POAG. However, the out-
comes of these investigations have been inconsistent, with some
studies demonstrating that CCBs are effective in lowering IOP,
protecting ganglion cells, increasing ocular blood ﬂow and
improving visual function while others fail to replicate those
results46–53. In all studies performed to date, however, CCBs have
targeted the α1 pore of the Ca2+ channel and have used a systemic
route of administration. None of the previous investigations
evaluated modulators of the Ca2+ channel auxiliary subunits, such
as CACNA2D1, nor have they evaluated topical delivery of the
drug. In our study, we demonstrate that targeting CACNA2D1
with topical pregabalin lowers IOP up to 30% in mice with the B
haplotype of the gene, which is a signiﬁcantly higher effect than
that demonstrated using systemically administered traditional
CCBs.
Previous human genomic studies (GWAS and linkage studies)
revealed multiple genomic regions that associated with elevated
IOP and/or POAG7, 9–11, 16. Two regions of interest lie on Chr 7q
near the locations of CACNA2D154–56 and CAV1/CAV27. Other
studies have demonstrated that SNPs in Cacna2d1/CACNA2D1
are associated with short QT syndrome38, perifosine cytotoxi-
city57, altered sensitivity to acute noxious heat58, and beef quality
traits59, indicating that polymorphisms in this gene have direct
and distinct physiological consequences, some of which may be
associated with modulation of IOP.
We show that CACNA2D1 is expressed in both CB and TM,
the sites of AH production, and outﬂow through the traditional
pathway, respectively, thus suggesting a possible role in AH
dynamics. It is also modestly present in the CM, a structure that
directly affects the distention of the TM in an antagonistic
manner3. We also demonstrate that the Cacna2d1 likely functions
in a network that includes other modulators of metal ion channel
and transport activity. Based upon these collective data, we pro-
pose a model for the role of CACNA2D1 in regulating IOP
(Fig. 6). Pregabalin, or other gabapentinoid drugs, binds to the
CACNA2D1 subunit of the calcium channel, the afﬁnity of which
varies depending on the haplotype of the gene. The binding of the
drug mitigates the ﬂux of Ca2+ through the α1 pore of the calcium
channel, reducing the level of intracellular Ca2+. A reduction in
Ca2+ could cause a concomitant reduction in ion transport, water
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Fig. 5 Cacna2d1 haplotype effects IOP-lowering potency of pregabalin, a
speciﬁc modulator of CACNA2D1, lowers IOP in B6 mice in a dose-
dependent manner. a We measured a dose-dependent reduction in IOP
compared to control treatment after a single application of ophthalmic
formulation containing a range of concentrations of pregabalin from 0.3 to
1.2%. The minimal concentration required to produce the maximum
reduction in IOP is 0.9% (mean± SEM; n= 6). Statistical details are
provided in Table 1. b Pregabalin-induced IOP reduction is haplotype-
speciﬁc. Mice carrying the B parental allele of Cacna2d1 (i.e., B6 and BXD14)
are more responsive to pregabalin (0.9%) than mice carrying the D
parental allele (i.e., D2 and BXD48; mean± SEM; n= 4–6). Statistical
details are provided in Table 2. c A single dose of pregabalin eye drops
(0.9%) lowers IOP by 22.1% in Dutch belted rabbits. n= 5. Statistical
details are provided in Table 3
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transfer, and contraction of smooth muscle cells. The net result of
pregabalin binding to CACNA2D1 could be threefold: a reduc-
tion in the production of AH by the CB; a relaxation of the TM
and resultant facilitation of the outﬂow of AH; and relaxation of
the CM, which would have an antagonistic effect on TM
relaxation. Given the marked effect that pregabalin has on base-
line IOP in BXD mice carrying the B haplotype of Cacna2d1, we
predict that the balance between the effect of the drug on TM
cells and also CM cells would be in favor of increased outﬂow
through the TM. If our hypothesis is valid, pregabalin binding to
both CB and TM, could both reduce AH production and increase
AH outﬂow.
In summary, our study identiﬁed Cacna2d1 as a modiﬁer of
IOP. We offer a hypothesis regarding the modulation of IOP and
Table 1 Pharmacodynamic parameters after application of drops containing four concentrations of pregabalin to the eyes of B6
mice
Pharmacodynamic parameters (mean± SEM) Pregabalin eye drops
0.3% 0.6% 0.9% 1.2%
Baseline IOP (mmHg) 15.4± 0.3 15.4± 0.1 15.3± 0.1 15.5± 0.1
IOP at Tmax (mmHg) — 14.2± 0.7 12.7± 0.8 12.6± 0.8
ΔIOP (mmHg) — −1.2± 0.8 −2.7± 0.8 −2.9± 0.9
% Reduction in IOP — 7.8± 4.8 17.3± 5.4 18.4± 5.6
Tmax (h) — 3.0± 0.4 2.8± 0.5 3.4± 0.4
Tend (h) — 5.5± 0.3 6.0± 0.4 6.8± 0.2
AUCtotal (% h) — 42.9± 11.1 67.1± 19.1 71.9± 12.1
Statistical comparisons among four concentrations of pregabalin drops applied to the eyes of B6 mice
Pharmacodynamic parameters
(mean± SEM)
Overall P-value 0.3% vs. 0.6% 0.3% vs. 0.9% 0.3% vs. 1.2% 0.6% vs. 0.9% 0.6% vs. 1.2% 0.9% vs. 1.2%
% Reduction in IOP 0.034 >0.05 >0.05 <0.05 >0.05 >0.05 >0.05
Tmax (h) <0.0001 <0.001 <0.001 <0.0001 >0.05 >0.05 >0.05
Tend (h) <0.0001 <0.0001 <0.0001 <0.0001 >0.05 <0.05 >0.05
AUCtotal (% h) 0.002 >0.05 <0.01 <0.01 >0.05 >0.05 >0.05
Overall P-value represents the outcome of the one-way ANOVA analysis. Individual P-values represent the outcome of Tukey–Kramer multiple comparisons tests. AUCtotal (% h) area under the curve in
percent IOP reduction x hours, Tend (h) time to end of response in hours, Tmax (h) time to maximum response in hours
Table 2 Pharmacodynamic parameters after application of 0.9% pregabalin eye drops to D2, BXD48 (D allele), B6, and BXD14
(B allele) mice
Pharmacodynamic parameters (mean± SEM) Mouse strain
D2 BXD48 B6 BXD14
Baseline IOP (mmHg) 17.2± 0.3 16.8± 0.5 15.3± 0.1 17.8± 0.6
IOP at Tmax (mmHg) — 14.4± 0.7 12.7± 0.8 12.7± 0.5
ΔIOP (mmHg) — −2.4± 0.6 −2.7± 0.8 −5.1± 0.8
% Reduction in IOP — 14.3± 3.9 17.3± 5.4 28.6± 3.5
Tmax (h) — 1.5± 0.2 2.8± 0.5 3.2± 0.3
Tend (h) — 3.0± 0.5 6.0± 0.4 6.5± 0.3
AUCtotal (% h) — 26.6± 4.5 67.1± 19.1 88.7± 12.6
Statistical comparisons among different strains of mice after application of 0.9% pregabalin eye drops
Pharmacodynamic parameters
(mean± SEM)
Overall P-value D2 vs. BXD48 D2 vs. B6 D2 vs. BXD14 BXD48 vs. B6 BXD48 vs. BXD14 B6 vs. BXD14
% Reduction in IOP 0.001 >0.05 >0.05 <0.001 >0.05 <0.05 >0.05
Tmax (h) <0.0001 <0.05 <0.001 <0.0001 <0.05 <0.01 >0.05
Tend (h) <0.0001 <0.001 <0.0001 <0.0001 <0.001 <0.0001 >0.05
AUCtotal (% h) 0.0002 >0.05 <0.01 <0.001 >0.05 <0.01 >0.05
Overall P-value represents the outcome of the one-way ANOVA analysis. Individual AUC-values represent the outcome of Tukey–Kramer multiple comparisons tests. AUCtotal (% h) area under the curve
in percent IOP reduction x hours, Tend (h) time to end of response in hours, Tmax (h) time to maximum response in hours
Table 3 Pharmacodynamic parameters after application of
0.9% pregabalin eye drops to Dutch belted rabbits
Pharmacodynamic parameters (Mean± SEM)
Baseline IOP (mmHg) 20.7± 0.5
IOP at Tmax (mmHg) 16.1± 1.4
ΔIOP (mmHg) −4.6± 0.6
% Reduction in IOP 22.1± 2.8
Tmax (h) 2.4± 0.6
Tend (h) 6.0± 0.0
AUCtotal (% h) 78.2± 4.2
AUCtotal (% h) area under the curve in percent IOP reduction x hours, Tend (h) time to end of
response in hours, Tmax (h) time to maximum response in hours
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offer a potential therapeutic target that could preserve vision by
reducing IOP. In the future, a similar approach could provide a
bridge between systems biology and effective drug target
identiﬁcation.
Methods
Animals. A total of 65 BXD strains, parents, and F1 crosses (548 mice at
9.1–13 months age) were used for QTL mapping of IOP in mice aged
9.1–13 months. The gender distribution was relatively equal (313 females and 235
males). IOP measured from 64 BXD strains aged 1–2.1 months (data available on
GeneNetwork) were used for comparison. The parental strains C57BL/6J (n= 6;
aged 3–5 months), DBA/2J (n= 4; aged 3–5 months), and two BXD strains—
BXD14 and BXD48 (n = 6; aged 3–5 months)—were used to evaluate the IOP-
lowering effects of pregabalin. C57BL/6 J and DBA/2 J were used as controls.
BXD14 and BXD48 strains were selected based on presence of the B and D hap-
lotype of Cacna2d1, respectively. Dutch belted rabbits (n= 5; procured from
Robinson Services, Mocksville, NC, USA) weighing ~2.0–2.5 kg were used to test
IOP-lowering effects of pregabalin. All procedures involving mice and rabbits were
approved by the Animal Care and Use review board of the University of Tennessee
Health Science Center (UTHSC) and followed the Association of Research in
Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and
Vision Research in addition to the guidelines for laboratory animal experiments
(Institute of Laboratory Animal Resources, Public Health Service Policy on
Humane Care and Use of Laboratory Animals). Animals were housed under cyclic
light (12 h on:12 h off) with 35% humidity in a speciﬁc pathogen-free facility at
UTHSC, and were allowed free access to water and food.
Human donor tissue. Our research and the protocol for collection of human
retinas were conducted in accordance with the tenets of the Declaration of Helsinki
and approved by University of Tennessee Health Science Center Institutional
Review Board. Informed consent was received from donors or donor family
members. Parafﬁn sections from a human donor eye (70-year-old, male) with no
diagnosis of ocular disease were obtained from National Disease Research Inter-
change (Philadelphia, PA). No donor details apart from age, sex, and cause of death
were provided.
IOP measurement. IOP of mice was measured using an induction-impact ton-
ometer (Tonolab tonometer, Colonial Medical Supply, Franconia, NH) for rodents
according to the manufacturer’s recommended procedures. The IOP of rabbits was
measured using a Tono-Pen AVIA (Reichert Technologies, Depew, NY) while
rabbits were held in a rabbit restrainer. Six consecutive IOP readings were aver-
aged. For each mouse, the tested ophthalmic formulation (10 μl) was applied to the
right eye, while the left eye received the blank and serve as a control29, 60. One
hundred microliters of 0.9% pregabalin eye drops were applied into the inferior
conjunctival sac of the right eye of the Dutch belted rabbits, while the left eye
received the blank eye drops61. All results were expressed as the mean percentage
reduction in IOP from baseline (mean% reduction ± SEM).
Identiﬁcation of IOP-modulating loci in mice. IOP data generated from 9.1–13-
month-old BXD strains was integrated into the GeneNetwork database. The
identiﬁcation and mapping of phenotypic QTL was performed by linking trait data
to genotypes at known genetic marker loci using the WebQTL module on Gene-
Network (http://www.genenetwork.org/)26, 29, 30, 32.
Evaluation of CACNA2D1 in GWAS repositories. SNPs located within the
CACNA2D1 human genomic region were evaluated in the NEIGHBORHOOD
consortium metadata16. To capture regulatory regions, the genomic locus was
deﬁned as all coding sequences + 50 base pairs on either side of the ﬁrst/last exon.
eQTL analysis of IOP candidate genes. IOP data from BXD mice aged
1–2.1 months (64 strains) and 9.1–13 months (65 strains) are publically available as
BXD published phenotypes record IDs 16337 (http://www.gn2.genenetwork.org/
show_trait?trait_id=16337&dataset=BXDPublish) and 16340 (http://www.gn2.
genenetwork.org/show_trait?trait_id=16340&dataset=BXDPublish), respectively.
Candidate genes were identiﬁed using the tools available on the GeneNetwork/
UCSC Genome browser. Gene expression was used as a microtrait to map reg-
ulatory eQTLs for the differences in mRNA expression levels over the panel of
BXD lines because it is a heritable trait. Whole-eye transcript data from BXD
strains available on GeneNetwork as Eye M430v2 (Sep08) RMA (http://www.
genenetwork.org/webqtl/main.py?FormID=sharinginfo&GN_AccessionId=207)
were used to identify cis (locally)-regulated genes from within intervals of inter-
est34. The same transcript data were used to identify genes whose expression
correlated with IOP at 9.1–13 months of age. Only probes that did not bind to
regions containing SNPs were used to avoid hybridization artifacts that may cause
differences in expression due to technical error rather than biological variance. All
probes were veriﬁed by BLAST-like alignment tool (BLAT) (University of
California Santa Cruz (UCSC) Genome Browser). Correlation analyses for initial
candidate gene selection used Pearson correlation coefﬁcients. Genes were con-
sidered as being cis-regulated if the associated marker was localized within a 10Mb
distance of the gene position34.
Gene set enrichment analysis. GSEA was performed as described previously
using version 2.2.0 (http://www.broadinstitute.org/gsea35, 62). Brieﬂy, all nominally
signiﬁcant correlates (uncorrected P≤ 0.05, 1603 genes) of Cacna2d1 were
extracted from the whole-eye transcript data and pre-ranked based on their cor-
relation coefﬁcients (Supplementary Data 1). Molecular Signatures Database
(MSigDB) version 5.0 was used as the database to perform GSEA. GSEA was
performed on these pre-ranked genes using 1000 permutations. This was followed
by building modules of related pathways based on at least 25% gene overlap
between pathways using the enrichment map strategy. The enrichment score (ES)
was calculated as cumulative score from 0. The ES was normalized to account for
the size of the gene set being used. To control the expected proportions of false
positives, the FDR for P-values was calculated using the Benjamini and Hochberg
method implemented in LIMMA.
Immunohistochemistry. Our standard methods were used to immunolocalize
CACNA2D1 in mouse and human eye sections30, 63, 64. An anti-CACNA2D1
antibody (Bioss Antibodies, Woburn, MA; catalog #bs-11981R; 1:100) was used in
these studies along with goat anti-rabbit Alexa ﬂuor 488 secondary antibody
(Invitrogen, Waltham, MA; catalog #A11034; 1:200), and TO-PRO-3 iodide
(Invitrogen, Waltham, MA; catalog #T3605) as a nuclear counterstain. Sections
were viewed and images were obtained using a Nikon C1 confocal microscope
(Nikon, NY).
Topical pregabalin ophthalmic formulations. Blank ophthalmic eye drops were
prepared by dissolving 2% hydroxypropylmethylcellulose (Sigma-Aldrich, St.
Louis, MO) in PBS pH 7.4 to use it as a vehicle (80%) in combination with
propylene glycol (10%; Sigma-Aldrich) and PEG 300 (10%; Sigma-Aldrich).
Pregabalin (Sigma-Aldrich, St. Louis, MO) ophthalmic eye drops were prepared
Epithelial
secretory activity 
AH production
(ciliary body)
IOP
AH outflow
(trabecular meshwork
and/or
ciliary muscle)
Water transfer
Smooth muscle
relaxation
Cytoskeletal
remodeling
Ca2+
homeostasisExtracellular
Pregabalin
Intracellular
α2
Ca2+
Ca2+
s-s
δ
γ α1
β
Fig. 6 Proposed mechanism of IOP reduction by pregabalin. We predict that pregabalin binds to CACNA2D1 localized to CB, TM, and/or CM cells.
Pregabalin binding causes the α1 pore to close, leading to a decrease in Ca2+ inﬂux into cells and a resultant decrease in free cytosolic Ca2+. Consequently,
the cells relax and aqueous humor inﬂow may be reduced and/or outﬂow may be increased, leading to a reduction in IOP
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using four different concentrations of the drug (0.3, 0.6, 0.9, and 1.2%) by dis-
solving pregabalin in the previously prepared blank ophthalmic eye drops. These
studies were conducted using a single dose–response design. Ten microliters of the
pregabalin formulations or the blank ophthalmic eye drops were used in the mouse
studies60 (n = 4–6). One hundred microliters of either formulation were used in the
rabbit study (n= 5). IOP was measured prior to treatment and hourly until the IOP
returned to baseline levels.
Several pharmacodynamics parameters were used to evaluate pregabalin
including maximum reduction in IOP (% reduction in IOP), time required to reach
maximum decrease of IOP (Tmax), time required for IOP to return to baseline (i.e.,
end of drug effect; Tend), and total area under the percent reduction in IOP-vs-time
curve (AUCtotal). Values of AUCtotal were determined using a linear trapezoidal
method65. Results were reported as mean± SEM.
Statistics. To determine how much of the variation in candidate gene across the
cohort was due to genetic effects, we calculated the heritability of the candidate
gene using the formula of Hegmann and Possidente26, 32, 33. Pearson product-
moment correlations were calculated using the Correlation matrix tool available in
GeneNetwork. Pearson correlation, denoted by r, measures the strength of a linear
association between two variables, which in our case are IOP (mmHg) and Cac-
na2d1 mRNA expression. Partial correlation within-strain and between-strain
variances, genotypes vs. IOP, and genotype vs. gene expression were calculated
with analysis of variance (ANOVA) using SAS 6.0. (Cary, NC) or GraphPad Prism-
7 software (La Jolla, CA). Statistical analyses of the pharmacodynamics results for
pregabalin were performed using one-way ANOVA with Tukey–Kramer multiple
comparisons test. All pharmacodynamic parameters as well as the statistical ana-
lysis of the results were also calculated using GraphPad Prism-7 software (La Jolla,
CA).
Data availability. The data sets generated during and/or analyzed during the
current study are available in the GeneNetwork repository as follows: IOP data
from BXD mice aged 1–2.1 months and 9.1–13 months are publically available as
BXD published phenotypes record IDs 16337 (http://www.gn2.genenetwork.org/
show_trait?trait_id=16337&dataset=BXDPublish) and 16340, (http://www.gn2.
genenetwork.org/show_trait?trait_id=16340&dataset=BXDPublish), respectively.
Cacna2d1 expression data is available as Trait ID 1446324_at and 1449999_a_at in
the Eye M430v2 (Sep08) RMA database (http://www.genenetwork.org/webqtl/
main.py?FormID=sharinginfo&GN_AccessionId=207).
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